Shufeng Xingbi Therapy Modulates Immune Balance and Gut Microbiota in Allergic Rhinitis: Insights from a Rat Model

Study Background and Research Question

Allergic rhinitis (AR) is a chronic, non-infectious inflammatory disorder of the nasal mucosa, characterized by symptoms such as paroxysmal sneezing, watery nasal discharge, nasal itching, and congestion. Epidemiological data indicate that AR affects over 10% of the global population, with incidence rising in recent decades, substantially impairing quality of life and increasing healthcare burden. The disease is primarily mediated by immunoglobulin E (IgE)-driven hypersensitivity to environmental allergens and is closely linked to Th1/Th2 immune imbalance. While current pharmacotherapies—including glucocorticoids, antihistamines, and leukotriene receptor antagonists—can acutely relieve symptoms, they often entail local or systemic side effects, especially in pediatric populations.

Emerging research underscores the role of the intestinal microbiota in regulating immune responses and influencing allergic outcomes, as highlighted by the "hygiene hypothesis" and studies on gut-lung axis signaling. Short-chain fatty acids (SCFAs) derived from microbial fermentation have been implicated in immune modulation and respiratory health. Within this landscape, the referenced study (bioRxiv preprint) investigates whether Shufeng Xingbi Therapy (SFXBT), a traditional Chinese medicine regimen, can modify Th1/Th2 immune balance and intestinal flora composition in a rat model of AR.

Key Innovation from the Reference Study

The principal innovation of the study lies in its integrative approach—simultaneously assessing immune polarization and gut microbial changes in response to SFXBT. The experimental design moves beyond symptom assessment to interrogate mechanistic pathways, including the expression of key transcription factors (STAT5, STAT6, GATA3), cytokine profiles, and fecal microbiota composition at both phylum and genus levels. This dual focus enables the elucidation of how herbal interventions might exert systemic anti-inflammatory effects through modulation of both host immunity and the gut microenvironment, a relatively underexplored axis in AR research.

Methods and Experimental Design Insights

• Animal Model: Thirty-two male Sprague Dawley rats (6 weeks old, 200–250 g) were randomized into four groups: control, OVA-induced AR, antibiotic + SFXBT, and acetic acid + SFXBT.
• AR Induction: Allergic rhinitis was induced via ovalbumin (OVA) sensitization and challenge, a widely validated method for modeling IgE-mediated nasal inflammation.
• Intervention: SFXBT was administered orally (recipe) and via nasal drops (gel formulation), reflecting clinical practice in traditional Chinese medicine.
• Behavioral and Histological Assessment: AR symptom scores and nasal mucosa pathology were evaluated via established scoring systems and H&E staining.
• Immunological Profiling: Serum IgE, interleukin-4 (IL-4), and SCFA levels were quantified by ELISA. Expression of transcription factors (STAT5, STAT6, GATA3) was measured at the mRNA level (RT-qPCR) and protein level (Western blot) in nasal mucosa.
• Microbiota Analysis: 16S rDNA sequencing of colonic contents provided taxonomic resolution of fecal microbiota alterations at phylum and genus levels.

Protocol Parameters

• OVA Sensitization: Use 10% OVA with aluminum hydroxide adjuvant for initial sensitization, followed by repeated nasal OVA challenges to induce AR symptoms in rats.
• SFXBT Administration: Oral dosing daily for 14 days, with concomitant nasal drops, mirroring dual-route clinical protocols.
• Antibiotic/Acetic Acid Pre-treatment: Pretreat selected groups with broad-spectrum antibiotics or acetic acid to modulate baseline gut microbiota before SFXBT intervention.
• Sample Collection: Collect serum, nasal mucosa, and colonic contents for integrated analysis of immune, histological, and microbial endpoints.

Core Findings and Why They Matter

Key results from the study reveal that both antibiotic + SFXBT and acetic acid + SFXBT groups exhibited significantly lower AR behavioral scores and ameliorated nasal mucosa pathology compared to the OVA group. Immunologically, SFXBT treatment led to reduced serum IgE and IL-4 levels, increased SCFA content, and downregulation of Th2-associated transcription factors and cytokines (STAT5, STAT6, GATA3, IL-4) in nasal tissues at both mRNA and protein levels.

Microbiota profiling demonstrated a notable increase in the relative abundance of Firmicutes and a decrease in Bacteroidetes at the phylum level, alongside a marked rise in beneficial genera such as Lactobacillus, Romboutsia, Allobaculum, and Dubosiella. These changes are consistent with existing evidence linking increased Firmicutes and SCFA-producing genera to anti-inflammatory outcomes. The coordinated improvement in immune balance and microbial composition supports the hypothesis that SFXBT's efficacy in AR derives from modulation of the gut-immune axis, not merely symptomatic relief.

Comparison with Existing Internal Articles

Recent internal thought-leadership articles, such as "Metronidazole as a Strategic Engine for Translational Research" and "Metronidazole in Translational Research: Mechanistic Insights", have emphasized the centrality of microbiota-immune axis research in translational immunology. These resources discuss how molecules like Metronidazole (2-(2-methyl-5-nitroimidazol-1-yl)ethanol), traditionally used as a nitroimidazole antibiotic, also act as potent inhibitors of organic anion transporters, with downstream effects on drug-drug interaction modulation and experimental immunomodulation. The referenced SFXBT study complements this paradigm by demonstrating that interventions targeting the gut microbiota can meaningfully impact Th1/Th2 polarization and allergic inflammation in vivo.

While the internal articles focus on pharmacological tools for in vitro and in vivo modulation of the gut-immune axis, the present study provides direct in vivo evidence that herbal therapeutics can induce comparable shifts in microbial ecology and immune homeostasis. This convergence underscores the growing importance of integrating microbiota-targeted strategies with immunological endpoints in allergy and inflammation research.

Limitations and Transferability

Despite its strengths, the study has limitations that warrant consideration. First, it employs a rat model, and while OVA-induced AR is a well-accepted surrogate for human disease, species differences may affect transferability. The precise composition of SFXBT (herbal recipe and gel) may vary depending on formulation and source, posing challenges for reproducibility outside controlled settings. The study does not dissect the relative contributions of oral versus nasal SFXBT administration, nor does it clarify which microbial changes are causally linked to immune modulation versus secondary to reduced inflammation.

Additionally, while the study demonstrates significant shifts at phylum and genus levels, deeper metagenomic or metabolomic analysis would be needed to resolve strain-level changes and functional pathway alterations. The findings are nonetheless a valuable proof-of-principle for the therapeutic potential of microbiota-immune axis interventions in allergic airway disease.

Why this cross-domain matters, maturity, and limitations

The intersection of microbiota modulation and immune balance is increasingly recognized as a critical domain in immunology, allergy, and drug development. The referenced study's demonstration that SFXBT can shape the gut microbiota and recalibrate Th1/Th2 polarization in vivo bridges traditional herbal medicine and contemporary immunopharmacology. While the evidence base for such interventions is maturing, translation to human clinical practice will require rigorous, controlled trials and standardized formulations. The current evidence is most mature in preclinical models, with human data still emerging.

Research Support Resources

For researchers aiming to dissect gut-immune interactions and transporter-mediated mechanisms, high-quality reagents are essential. Metronidazole (2-(2-methyl-5-nitroimidazol-1-yl)ethanol, SKU B1976) from APExBIO offers a validated tool for studying inhibition of organic anion transporters and for in vitro or in vivo modulation of intestinal microbiota. Its documented effects on both anaerobic bacteria targeting and drug-drug interaction modulation, as described in internal workflow resources, make it suitable for experimental setups analogous to those used in the SFXBT study. Metronidazole's purity and stability specifications further support reproducible research outcomes in microbiota-immune axis experiments.